Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 26,800 shares of the biopharmaceutical company’s stock after selling 6,253 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $16,078,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Merit Financial Group LLC increased its holdings in Regeneron Pharmaceuticals by 302.4% in the third quarter. Merit Financial Group LLC now owns 1,859 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 1,397 shares in the last quarter. Marietta Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 5.0% during the 3rd quarter. Marietta Wealth Management LLC now owns 12,025 shares of the biopharmaceutical company’s stock valued at $6,761,000 after acquiring an additional 574 shares during the period. Generate Investment Management Ltd increased its stake in shares of Regeneron Pharmaceuticals by 56.5% in the 3rd quarter. Generate Investment Management Ltd now owns 18,778 shares of the biopharmaceutical company’s stock valued at $10,558,000 after purchasing an additional 6,778 shares in the last quarter. Forefront Wealth Partners LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $326,000. Finally, Simplify Asset Management Inc. boosted its position in Regeneron Pharmaceuticals by 251.1% during the third quarter. Simplify Asset Management Inc. now owns 12,981 shares of the biopharmaceutical company’s stock worth $7,299,000 after purchasing an additional 9,284 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.6%

REGN stock opened at $776.31 on Monday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $723.10 and a two-hundred day moving average of $619.90. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $792.77. The company has a market cap of $81.59 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 2.31 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the prior year, the business earned $12.46 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on REGN. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Finally, Scotiabank raised their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $779.45.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.